Quinolone Resistance in Bloodstream Isolates of Escherichia Coli

Completed

Conditions studied: Bacterial Infections

In brief

This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of E. coli. Additionally, the adequacy of empiric antibiotic therapy for E. coli bloodstream infections will be assessed. Finally, outcome will be recorded - this is all-cause mortality at 28 days from the time of the first positive blood culture. Hypothesis: Ciprofloxacin resistant strains are associated with admission from nursing home and with prior quinolone use.

Key facts

Study ID

NCT00449735

Run by

University of Pittsburgh

People needed

500

Starts

2007-03-01

Expected to finish

2017-06-01

Last updated by the study team

2018-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical information is collected by chart review of "case" and "control" patients.
• A "case A" patient is defined as follows:
• One or more blood cultures are positive for E. coli. The organism is ciprofloxacin resistant.
• A "case B" patient is defined as follows:
• One or more blood cultures are positive for E. coli. The organism is ciprofloxacin susceptible. Additionally, 4 controls who are in hospital at the same time as cases will be selected for each case.

You may not qualify if…

• If they do not meet inclusion criteria

Where it is running

• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.